{
    "title": "AstraZeneca boosts oncology credentials with breast cancer trial success",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-10534471/AstraZenecas-Enhertu-shows-promise-broader-breast-cancer-use.html",
    "date": "2022-02-21",
    "keywords": [
        "cancer",
        "drug",
        "breast",
        "her2",
        "group",
        "patient",
        "disease",
        "enhertu",
        "treatment",
        "sankyo",
        "trial",
        "use",
        "study",
        "readout",
        "companys",
        "development",
        "lung",
        "burger",
        "type",
        "door",
        "astrazeneca",
        "monday",
        "survival",
        "progression",
        "protein",
        "improvement",
        "chemotherapy",
        "latestage",
        "asyet",
        "conference",
        "company",
        "review",
        "wider",
        "body",
        "year",
        "status",
        "pharma",
        "success",
        "rate",
        "decline",
        "covid19",
        "vaccine",
        "tagrisso",
        "kidney",
        "gmt",
        "increase",
        "stoxx",
        "health",
        "care",
        "index",
        "gain",
        "trading",
        "pool",
        "credit",
        "suisse",
        "note",
        "probability",
        "potential",
        "compound",
        "deal",
        "maker",
        "categorisation",
        "number",
        "galbraith",
        "head",
        "oncology",
        "research",
        "test",
        "class",
        "market",
        "approval",
        "clearance",
        "colorectal",
        "receptor",
        "punch",
        "reporting",
        "pushkala",
        "aripaka",
        "bengaluru",
        "editing",
        "dasgupta",
        "jason",
        "donovan"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}